BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 6548172)

  • 21. Chemotherapy for stage III-IV ovarian cancer: the CAP-regimen in previously untreated patients.
    Meerpohl HG; Pfleiderer A; Kleine W; Teufel G
    Onkologie; 1982 Oct; 5(5):238-41. PubMed ID: 6760025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of the combination of cisplatin, adriamycin and cyclophosphamide in the treatment of ovarian carcinoma.
    Russo A; Gebbia V; Palmeri S; Geraci P; Maneschi F; Guarnieri G; Carollo F; Leonardi V; Meli M; Gebbia N
    Eur J Gynaecol Oncol; 1993; 14(3):228-33. PubMed ID: 8508880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of fallopian tube carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
    Morris M; Gershenson DM; Burke TW; Kavanagh JJ; Silva EG; Wharton JT
    Obstet Gynecol; 1990 Dec; 76(6):1020-4. PubMed ID: 2234710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.
    du Bois A; Meerpohl HG; Madjar H; Spinner D; Dall P; Pfisterer J; Bauknecht T
    J Cancer Res Clin Oncol; 1994; 120(3):173-8. PubMed ID: 8263015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cis-platin in combination with low dose adriamycin and cyclophosphamide in advanced ovarian carcinoma.
    Verheijen RH; Beex L; Wagener DJ; Kenemans P
    Eur J Gynaecol Oncol; 1985; 6(2):116-20. PubMed ID: 3839751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer.
    Hernádi Z; Juhász B; Póka R; Lampé LG
    Int J Gynaecol Obstet; 1988 Oct; 27(2):199-204. PubMed ID: 2903085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
    Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide, adriamycin and cisplatin (CAP) versus cyclophosphamide, adriamycin and vincristin (CAV) in the treatment of advanced ovarian cancer: a randomized study.
    Krommer CF; Szalai JP
    Ann Oncol; 1992 Jan; 3(1):37-9. PubMed ID: 1606067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival after chemotherapy with cisplatinum, adriamycin and cyclophosphamide for carcinoma of the ovary.
    Davidson NG; Khanna S; Kirwan PH; Naftalin NJ; Roy UK; Chui D; Mitchell S
    Clin Oncol (R Coll Radiol); 1990 Jul; 2(4):206-9. PubMed ID: 2261416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
    Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
    Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
    Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
    J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.